Dyslipidemia, a significant risk factor for cardiovascular disease, is characterized by abnormal lipid levels in the bloodstream. This article provides an overview of dyslipidemia's pathophysiology and management strategies for clinicians.
Dyslipidemia can be primary, due to genetic predisposition, or secondary, resulting from lifestyle factors or other medical conditions. It encompasses several disorders, including high low-density lipoprotein cholesterol (LDL-C), low high-density lipoprotein cholesterol (HDL-C), and high triglyceride levels. These lipid abnormalities contribute to atherosclerosis, leading to cardiovascular diseases.
Diagnosis is typically based on fasting lipid profile tests, revealing elevated LDL-C, total cholesterol, and triglycerides, or decreased HDL-C. Genetic testing may be beneficial in cases of suspected familial hypercholesterolemia.
Management of dyslipidemia includes lifestyle modification and pharmacotherapy. Lifestyle changes encompass dietary modifications, physical activity, and smoking cessation. Pharmacological interventions include statins, bile acid sequestrants, cholesterol absorption inhibitors, fibrates, niacin, and PCSK9 inhibitors. The choice of therapy depends on the type and severity of dyslipidemia, patient's cardiovascular risk, and potential drug interactions.
Regular monitoring of lipid levels and patient adherence to therapy is essential. The frequency of follow-up depends on the patient's initial lipid levels, response to treatment, and overall cardiovascular risk.
In summary, understanding the pathophysiology and management of dyslipidemia is crucial in reducing the burden of cardiovascular diseases. A patient-centered approach, involving lifestyle modifications, pharmacotherapy, and regular monitoring, can effectively manage dyslipidemia and mitigate cardiovascular risk.
1.
A smartphone app enhances the tracking of recovery following breast and gynecologic oncology surgery, according to JAMA.
2.
Mezigdomide Combinations Show Promise in Multiple Myeloma
3.
Adult survivors of childhood cancer are at high risk for cognitive impairment, according to JAMA.
4.
Both DNA damage repair deficiency and non-Hodgkin lymphoma are the focus of LP-284.
5.
Oleanolic acid from grapes may increase chemotherapy effectiveness
1.
Advanced Approaches in Oncology and Patient Outcomes
2.
Unraveling the Mysteries of Hematocrit: How It Impacts Your Health
3.
Emerging Advances in Hematology and Quality Improvement
4.
The Silent Signs: Uncovering Stomach Cancer Symptoms Before It's Too Late
5.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV
2.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
3.
Navigating the Complexities of Ph Negative ALL - Part XIV
4.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Important Points to Know
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation